2,4-dichloro-N-((1-(cyclopropylsulfonyl)-4-(pyridin-2-yl)piperidin-4-yl)methyl)benzamide

ID: ALA463025

Chembl Id: CHEMBL463025

PubChem CID: 11583581

Max Phase: Preclinical

Molecular Formula: C21H23Cl2N3O3S

Molecular Weight: 468.41

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NCC1(c2ccccn2)CCN(S(=O)(=O)C2CC2)CC1)c1ccc(Cl)cc1Cl

Standard InChI:  InChI=1S/C21H23Cl2N3O3S/c22-15-4-7-17(18(23)13-15)20(27)25-14-21(19-3-1-2-10-24-19)8-11-26(12-9-21)30(28,29)16-5-6-16/h1-4,7,10,13,16H,5-6,8-9,11-12,14H2,(H,25,27)

Standard InChI Key:  NTHIUNUSDAUDKD-UHFFFAOYSA-N

Associated Targets(Human)

SLC6A9 Tchem Glycine transporter 1 (2077 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A5 Tchem Glycine transporter 2 (697 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A6 Tbio Sodium- and chloride-dependent taurine transporter (65 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Canis familiaris (36305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 468.41Molecular Weight (Monoisotopic): 467.0837AlogP: 3.64#Rotatable Bonds: 6
Polar Surface Area: 79.37Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.40CX Basic pKa: 4.35CX LogP: 2.91CX LogD: 2.91
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.70Np Likeness Score: -1.66

References

1. Wolkenberg SE, Zhao Z, Wisnoski DD, Leister WH, O'Brien J, Lemaire W, Williams DL, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Gibson C, Ma BK, Polsky-Fisher SL, Lindsley CW, Hartman GD..  (2009)  Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.,  19  (5): [PMID:19181525] [10.1016/j.bmcl.2009.01.015]

Source